VRDN insider filings

Viridian Therapeutics, Inc.\DE — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-08-20. Screen VRDN transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for VRDN between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Viridian Therapeutics, Inc.\DE

FiledFormInsiderReported transactionsSource
2026-08-204Tousignant Jennifer — Chief Legal OfficerSale (S): 4,212 @ $24.50 · Option exercise (M): 10,000 @ $14.41 · Sale (S): 10,000 @ $24.50 · Option exercise (M): 10,000 (derivative) @ $0EDGAR
2026-08-184Tripuraneni Radhika — Chief Medical OfficerOption exercise (M): 40,000 @ $13.21 · Option exercise (M): 40,000 (derivative) @ $0EDGAR
2026-07-024CAIN CHRISTOPHER W. — DirectorGrant/award (A): 32,341 (derivative) @ $0EDGAR
2026-07-024Moses Jennifer K. — DirectorGrant/award (A): 32,341 (derivative) @ $0EDGAR
2026-07-024Gheuens Sarah — DirectorGrant/award (A): 32,341 (derivative) @ $0EDGAR
2026-07-024Kiselak Tomas — DirectorGrant/award (A): 32,341 (derivative) @ $0EDGAR
2026-07-024Ajer Jeffrey Robert — DirectorGrant/award (A): 32,341 (derivative) @ $0EDGAR
2026-07-024Morris Arlene — DirectorGrant/award (A): 32,341 (derivative) @ $0EDGAR
2026-05-134Fairmount Funds Management LLC — Director, 10% owner
Fairmount Healthcare Fund II GP LLC — Director, 10% owner
Fairmount Healthcare Fund II L.P. — Director, 10% owner
Purchase (P): 1,176,470 @ $17EDGAR
2026-03-094/AHarmon Seth — Chief Financial OfficerTax withholding (F): 2,031 @ $30.19EDGAR
2026-03-094/ABeetham Thomas W. — Chief Operating OfficerTax withholding (F): 3,048 @ $30.19EDGAR
2026-03-094/ATousignant Jennifer — Chief Legal OfficerTax withholding (F): 1,675 @ $30.19EDGAR
2026-03-094/AMahoney Stephen F. — President and CEO, DirectorTax withholding (F): 7,408 @ $30.19EDGAR
2026-03-044Tousignant Jennifer — Chief Legal OfficerOption exercise (M): 5,169 · Tax withholding (F): 1,724 @ $29.32 · Grant/award (A): 119,300 (derivative) @ $0 · Grant/award (A): 23,850 (derivative) @ $0 · Option exercise (M): 5,169 (derivative) @ $0EDGAR
2026-03-044Harmon Seth — Chief Financial OfficerOption exercise (M): 6,267 · Tax withholding (F): 2,091 @ $29.32 · Grant/award (A): 102,850 (derivative) @ $0 · Grant/award (A): 20,550 (derivative) @ $0 · Option exercise (M): 6,267 (derivative) @ $0EDGAR
2026-03-044Beetham Thomas W. — Chief Operating OfficerOption exercise (M): 9,409 · Tax withholding (F): 3,138 @ $29.32 · Grant/award (A): 176,550 (derivative) @ $0 · Grant/award (A): 35,300 (derivative) @ $0 · Option exercise (M): 9,409 (derivative) @ $0EDGAR
2026-03-044Mahoney Stephen F. — President and CEOOption exercise (M): 18,357 · Tax withholding (F): 7,627 @ $29.32 · Grant/award (A): 559,600 (derivative) @ $0 · Grant/award (A): 111,900 (derivative) @ $0 · Option exercise (M): 18,357 (derivative) @ $0EDGAR
2026-03-044Tripuraneni Radhika — Chief Medical OfficerGrant/award (A): 95,800 (derivative) @ $0 · Grant/award (A): 19,150 (derivative) @ $0EDGAR
2026-03-044/AHarmon Seth — Chief Financial OfficerHoldings only — no transactions reportedEDGAR
2026-03-044/ATousignant Jennifer — Chief Legal OfficerHoldings only — no transactions reportedEDGAR
2026-01-024Tousignant Jennifer — Chief Legal OfficerSale (S): 2,272 @ $31.16EDGAR
2025-10-274Fairmount Funds Management LLC — Director, 10% owner
Fairmount Healthcare Fund II GP LLC — Director, 10% owner
Fairmount Healthcare Fund II L.P. — Director, 10% owner
Purchase (P): 454,545 @ $22EDGAR
2025-07-024CAIN CHRISTOPHER W. — DirectorGrant/award (A): 21,000 (derivative) @ $0EDGAR
2025-07-024Kiselak Tomas — DirectorGrant/award (A): 21,000 (derivative) @ $0EDGAR
2025-07-024Gheuens Sarah — DirectorGrant/award (A): 21,000 (derivative) @ $0EDGAR
2025-07-024Moses Jennifer K. — DirectorGrant/award (A): 21,000 (derivative) @ $0EDGAR
2025-07-024Ajer Jeffrey Robert — DirectorGrant/award (A): 21,000 (derivative) @ $0EDGAR
2025-07-024Morris Arlene — DirectorGrant/award (A): 21,000 (derivative) @ $0EDGAR
2025-06-114Fairmount Funds Management LLC — Director, 10% owner
Fairmount Healthcare Fund II GP LLC — Director, 10% owner
Fairmount Healthcare Fund II L.P. — Director, 10% owner
Option exercise (M): 1,600 @ $7.80 · Option exercise (M): 12,500 @ $12.31 · Option exercise (M): 1,600 (derivative) @ $0 · Option exercise (M): 12,500 (derivative) @ $0EDGAR
2025-04-094Ajer Jeffrey Robert — DirectorGrant/award (A): 42,000 (derivative) @ $0EDGAR
2025-03-124Tripuraneni Radhika — Chief Medical OfficerGrant/award (A): 310,700 (derivative) @ $0EDGAR
2025-03-124CAIN CHRISTOPHER W. — DirectorGrant/award (A): 42,000 (derivative) @ $0EDGAR
2025-03-044Tousignant Jennifer — Chief Legal OfficerGrant/award (A): 124,072 (derivative) @ $0 · Grant/award (A): 20,679 (derivative) @ $0EDGAR
2025-03-044Mahoney Stephen F. — President and CEO, DirectorGrant/award (A): 440,565 (derivative) @ $0 · Grant/award (A): 73,428 (derivative) @ $0EDGAR
2025-03-044Beetham Thomas W. — Chief Operating OfficerGrant/award (A): 225,814 (derivative) @ $0 · Grant/award (A): 37,636 (derivative) @ $0EDGAR
2025-03-044Harmon Seth — Chief Financial OfficerGrant/award (A): 150,407 (derivative) @ $0 · Grant/award (A): 25,068 (derivative) @ $0EDGAR
2024-09-304Beetham Thomas W. — Chief Operating OfficerPurchase (P): 5,000 @ $23.41EDGAR
2024-09-304Mahoney Stephen F. — President and CEO, DirectorPurchase (P): 21,400 @ $23.33EDGAR
2024-09-174Fairmount Funds Management LLC — Director, 10% owner
Fairmount Healthcare Fund II GP LLC — Director, 10% owner
Fairmount Healthcare Fund II L.P. — Director, 10% owner
Purchase (P): 1,600,000 @ $18.75EDGAR
2024-06-284Gheuens Sarah — DirectorGrant/award (A): 21,000 (derivative) @ $0EDGAR
2024-06-284Harwin Peter Evan — DirectorGrant/award (A): 21,000 (derivative) @ $0EDGAR
2024-06-284Kiselak Tomas — DirectorGrant/award (A): 21,000 (derivative) @ $0EDGAR
2024-06-284Moses Jennifer K. — DirectorGrant/award (A): 21,000 (derivative) @ $0EDGAR
2024-06-284Morris Arlene — DirectorGrant/award (A): 21,000 (derivative) @ $0EDGAR
2024-04-014Fairmount Funds Management LLC — Director, 10% owner
Fairmount Healthcare Fund GP LLC — Director
Fairmount Healthcare Fund II GP LLC — Director, 10% owner
Fairmount Healthcare Fund L.P. — Director
Fairmount Healthcare Fund II L.P. — Director, 10% owner
Other (J): 5,859 · Other (J): 5,859 · Other (J): 21,999 (derivative) @ $0 · Other (J): 21,999 (derivative) @ $0EDGAR
2024-02-144Tousignant Jennifer — Chief Legal OfficerGrant/award (A): 290,000 (derivative) @ $0EDGAR
2024-02-074Ciulla Thomas — Chief Medical OfficerGrant/award (A): 50,000 (derivative) @ $0EDGAR
2024-01-244Fairmount Funds Management LLC — Director, 10% owner
Fairmount Healthcare Fund GP LLC — Director
Fairmount Healthcare Fund II GP LLC — Director, 10% owner
Fairmount Healthcare Fund L.P. — Director
Fairmount Healthcare Fund II L.P. — Director, 10% owner
Purchase (P): 476,190 @ $21EDGAR
2023-11-134Harmon Seth — See RemarksGrant/award (A): 270,000 (derivative) @ $0EDGAR
2023-11-014Fairmount Funds Management LLC — Director, 10% owner
Fairmount Healthcare Fund GP LLC — Director
Fairmount Healthcare Fund II GP LLC — Director
Fairmount Healthcare Fund L.P. — Director
Fairmount Healthcare Fund II L.P. — Director
Grant/award (A): 48,463 (derivative) @ $825.37EDGAR

Recent 8-K events — Viridian Therapeutics, Inc.\DE

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-098-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-11-048-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-068-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-298-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-038-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-05-288-K1.02 — Termination of a Material Definitive AgreementEDGAR
2026-05-268-K1.01 — Entry into a Material Definitive AgreementEDGAR
2026-05-118-K1.01 — Entry into a Material Definitive Agreement
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-058-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-058-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=VRDN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs